| Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health |
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). |
globenewswire.com |
2025-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update |
- End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-07 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes |
Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population Presentation Shows Pronounced Reduction in Key Plasma Biomarkers Among Prespecified Study Population |
globenewswire.com |
2025-04-01 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 |
Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement |
globenewswire.com |
2025-03-25 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript |
Cognition Therapeutics, Inc (NASDAQ:CGTX ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Daniil Gataulin - Chardan Operator Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call. |
seekingalpha.com |
2025-03-20 15:15:06 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update |
Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y. |
globenewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results |
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. |
globenewswire.com |
2025-03-13 18:05:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing |
PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by the Nasdaq Stock Market LLC (“Nasdaq”) on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance with the minimum bid price requirement, by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The period to regain compliance with the minimum bid price requirement closed on March 11, 2025. |
globenewswire.com |
2025-03-12 18:05:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference |
PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her presentation, Ms. Ricciardi will review plans for 2025 to support the advancement of zervimesine (CT1812) in Alzheimer's disease and dementia with Lewy bodies following the Company's positive Phase 2 data readouts. |
globenewswire.com |
2025-03-10 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD |
Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD |
globenewswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit |
PITTSBURGH, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ensure that the patients selected are most likely to benefit from treatment. |
globenewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC |
– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB – |
globenewswire.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences |
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025. |
globenewswire.com |
2025-01-08 18:14:00 |
Czytaj oryginał (ang.) |
| Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? |
Cognition Therapeutics, Inc. CGTX revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia with Lewy bodies (DLB). |
benzinga.com |
2024-12-18 13:06:11 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies |
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB). |
globenewswire.com |
2024-12-18 09:22:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
Cognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-11-28 12:56:21 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies |
– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). |
globenewswire.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population |
- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology - |
globenewswire.com |
2024-11-25 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update |
- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - |
globenewswire.com |
2024-11-13 09:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum |
PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company's presentation will focus primarily on the results from the successful Phase 2 ‘SHINE' study of CT1812 in mild-to-moderate Alzheimer's disease. In addition, Ms. Ricciardi will provide an overview of the Company's ongoing clinical programs, including the Phase 2 ‘SHIMMER' study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER' study are expected by year-end 2024. |
globenewswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| November's Small-Cap Treasures: 3 Stocks Poised for Growth |
November is often a lucrative period for small-cap stock market investments. Historically, the S&P 500 and the small-cap-focused Russell 2000 have delivered strong returns during the November-April stretch. |
marketbeat.com |
2024-11-04 09:45:04 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD |
- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER' study of mild-to-moderate dementia with Lewy bodies (DLB). |
globenewswire.com |
2024-10-31 18:15:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD |
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - |
globenewswire.com |
2024-10-29 14:55:00 |
Czytaj oryginał (ang.) |
| Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD |
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE' Poster Presentation details b aseline characteristics from the signal-finding ‘SHIMMER' trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain. |
globenewswire.com |
2024-10-23 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) |
PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness Month, is titled “Executing Clinical Research in Dementia with Lewy Bodies (DLB).” |
globenewswire.com |
2024-10-22 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference |
PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. |
globenewswire.com |
2024-10-02 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia |
Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 |
globenewswire.com |
2024-10-01 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences |
PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September. |
globenewswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease |
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease . SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions. |
globenewswire.com |
2024-08-22 11:31:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript |
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2024 Earnings Conference Call August 11, 2024 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, LLC Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Daniil Gataulin - Chardan Operator Hello, and thank you for standing by. |
seekingalpha.com |
2024-08-11 04:55:19 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update |
- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - |
globenewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| Cognition Therapeutics to Report Second Quarter 2024 Financial Results |
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - - Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - |
globenewswire.com |
2024-08-05 11:30:00 |
Czytaj oryginał (ang.) |
| Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? |
Cognition Therapeutics (NASDAQ: CGTX ) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 ‘SHINE' study. This study evaluated the effectiveness of treating patients with CT1812. |
investorplace.com |
2024-07-29 15:09:06 |
Czytaj oryginał (ang.) |